Home > Cardiology > ACC 2019 > Interventional Cardiology > Ticagrelor monotherapy safe after dual antiplatelet therapy

Ticagrelor monotherapy safe after dual antiplatelet therapy

Conference
ACC 2019
Trial
GLASSY

Data from the GLASSY trial, an adjudication sub-study of the GLOBAL LEADERS trial, showed that ticagrelor monotherapy after 1 month of dual antiplatelet therapy (DAPT) was non-inferior to conventional DAPT in the prevention of all-cause death, non-fatal myocardial infarction (MI), non-fatal stroke, or urgent target-vessel revascularisation (TVR) at 2 years [1].

Results from the GLOBAL LEADERS trial showed that ticagrelor with 1 month of aspirin did not reduce the composite of death or Q-wave myocardial infarction compared with 1 year of DAPT followed by aspirin [2]. By design, all clinical endpoints in the GLOBAL LEADERS trial were investigator-reported without central adjudication. The sub-study GLASSY was designed to prospectively implement an independent central adjudication process of both reported events and potentially unreported event triggers to further assess the impact of this novel experimental treatment in a large stratified sample of patients ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on